NB-PP_1170x120

FDA

CHPA conference to discuss issues affecting the industry and market

CHPA conference to discuss issues affecting the industry and market

WASHINGTON – The Consumer Healthcare Products Association (CHPA) will hold its 2019 Regulatory, Scientific & Quality Conference (RSQ), May 21 to 22 in North Bethesda, Md. to discuss key regulatory, scientific, quality, and legal issues impacting the consumer healthcare products industry, such as incorporating new technologies, innovative ways of thinking, and regulatory developments to advance consumer self-care. The

FDA issues statement on CBD products

FDA issues statement on CBD products

SILVER SPRING, Md. — FDA commissioner Scott Gottlieb, issued the following statement on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products: “In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and its components,

Sharpless named acting FDA commissioner

Sharpless named acting FDA commissioner

WASHINGTON — Dr. Norman “Ned” Sharpless, director of the National Cancer Institute, will become acting commissioner of the Food and Drug Administration next month. Health and Human Services Secretary Alex Azar said Tuesday that Sharpless will take the reins of the FDA after the resignation of Scott Gottlieb. The administration is seeking a permanent replacement

Gottlieb resigns as FDA commissioner

Gottlieb resigns as FDA commissioner

SILVER SPRING, Md. — Food and Drug Administration Commissioner Scott Gottlieb is resigning, effective in about a month. The 46-year-old Gottlieb, who has been commuting weekly to the FDA office here from his home in Connecticut, wants to spend more time with his family, an administration official told The Washington Post. Health and Human Services

WBA willing to meet with FDA over tobacco sales to minors

WBA willing to meet with FDA over tobacco sales to minors

DEERFIELD, Ill. — Walgreens said Tuesday it welcomed the opportunity to meet with Food and Drug Administration commissioner Scott Gottlieb to discuss the steps it is taking  to prevent the sale of tobacco products to minors. The retailer issued the statement after Gottlieb said the FDA had written to Walgreens “to request a meeting to

FDA issues statement on new policy for pricing of generic drugs

FDA issues statement on new policy for pricing of generic drugs

SILVER SPRING, Md. — FDA Commissioner Dr. Scott Gottlieb issued the following statement Friday on a new policy to improve access and foster price competition for drugs that face inadequate generic competition: “In too many cases, branded drugs that are no longer protected by patents or other exclusivities do not face expected competition. In fact,

CVS applauds FDA restricting flavored tobacco products

CVS applauds FDA restricting flavored tobacco products

WOONSOCKET, R.I. — CVS Health, the nation’s first and only national pharmacy chain to have eliminated the sale of tobacco products from its retail stores, today announced its support for the U.S. Food and Drug Administration’s plans to restrict access to flavored tobacco and e-cigarette products in the retail setting and impose stricter age-verification requirements for

CVS praises FDA’s steps to curtail sales of e-cigarettes to nation’s youth

CVS praises FDA’s steps to curtail sales of e-cigarettes to nation’s youth

WOONSOCKET, R.I. — As the nation’s first and only national pharmacy chain to have eliminated the sale of cigarettes and other harmful tobacco products from its retail stores and having never sold e-cigarettes and vaping devices CVS Health today applauded the enforcement actions taken by the U.S. Food and Drug Administration (FDA) to curtail the

FDA extends EpiPen expiration date to combat shortage

FDA extends EpiPen expiration date to combat shortage

WASHINGTON — Facing a national shortage of EpiPens, the Food and Drug Administration has extended the expiration dates of certain lots of the life-saving allergy drug by four months. The extensions apply to the 0.3 mg dose of EpiPen and its authorized generic, with current expiration dates between April and December 2018, according to a statement

PCMA issues statement on FDA biosimilar action plan

PCMA issues statement on FDA biosimilar action plan

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on the Food and Drug Administration’s (FDA) new Biosimilars Action Plan: “We applaud the FDA for taking important steps toward approving more biosimilars in the United States. We are encouraged the FDA has designed a system that allows manufacturers

Amazon said to hire ex-FDA staffer

SEATTLE — Amazon.com has hired Taha Kass-Hout, the Food and Drug Administration’s first chief health informatics officer, according to published reports. Kass-Hout will serve in a business development role with the company’s Amazon Grand Challenge team, the reports say, and will concentrate on developing projects for the health care market. His exact mission, like the

FDA acts to boost Rx drug competition

FDA acts to boost Rx drug competition

WASHINGTON — The Food and Drug Administration today announced two new steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of